White Paper: Accelerating Antibody-Drug Conjugate (ADC) Development

Antibody-drug conjugates (ADCs) bring together the complexity of biologics and small molecules, demanding more than traditional antibody workflows can offer. Their hybrid structure requires multi-analyte assessment to accurately capture pharmacokinetics and immunogenicity profiles. As ADC development scales, contract research organizations (CROs) face mounting pressure to streamline bio-analytical workflows without compromising sensitivity or reproducibility. Automated immunoassay platforms like Gyrolab® offer a solution to reduce hands-on time, improve throughput, and minimize sample consumption and matrix interference. This white paper explores how automation can overcome common bottlenecks in plate-based assays and includes case studies from preclinical and clinical programs that demonstrate the impact of multi-analyte workflows.

Download the white paper to deepen your understanding of ADC complexity and discover strategies to accelerate your development program.